Product Launch

Drug Approvals Need Shades Of Grey

Posted on Monday, November 12, 2012

FDA’s Endocrinologic and Metabolic drugs advisory committee on Nov. 8 voted 8-4 in favor of recommending Novo’s latest insulin degludec (Tresiba) for approval. The detailed debate and...

Learn More

Zaltrap: Now the Price is Right

Posted on Friday, November 9, 2012

Power to the payer. Just weeks after a team of Memorial Sloan Kettering Cancer Center physicians criticized the high price tag of Sanofi/Regeneron’s new angiogenesis inhibitor Zaltrap in a New York Times...

Learn More

The Healthcare Round-Up: 1/24 -1/31

Posted on Tuesday, January 31, 2012

Even as politicos geared up for today’s Florida primary, healthcare wonks are still shaking their heads at the fact that the Affordable Care Act –or healthcare generally—didn’t get much air time in President...

Learn More

AZ Takes RWE Deals To Europe With IMS Tie-Up

Posted on Friday, January 13, 2012

Less than a year after its tie-up with the outcomes division of U.S. insurer WellPoint, AZ’s now trying to increase its odds of gaining — and maintaining — healthy reimbursement for its new drugs...

Learn More